Skip to main content
. 2023 Feb 13;47(4):325–334. doi: 10.1038/s41366-023-01272-x

Fig. 6. TBK1 inhibition alleviated inflammatory activation in PA-treatment MH-S and RAW264.7 macrophages.

Fig. 6

MH-S and RAW264.7 macrophages were treated with PA (0.6 mM) for 24 h in the absence or presence of amlexanox (50 μM, 2 h before PA stimulation). a, b Representative western blots of the p-IRF3 (a), IRF3 (a), p-p65 (b) and p-65 (b) in PA-treated MH-S cells and RAW264.7 macrophages with or without amlexanox. cf Group data of p-IRF3/IRF3 (c, e) and p-p65/p65 (d, f) fold change in equal amounts of protein extracts of PA-treated MH-S cells and RAW264.7 macrophages with or without amlexanox. n = 3 biologically independent experiments in each group. g, h ELISA analysis showed that amlexanox decreased the levels of proinflammatory cytokines, including TNF-α, IL-6 and IFNβ in PA-treated MH-S cells (g) and RAW264.7 macrophages (h). n = 3 biologically independent experiments. Data represent mean ± SD. Statistical significance was determined using two-tailed Student’s t test.